Overview

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

Status:
Completed
Trial end date:
2023-07-13
Target enrollment:
Participant gender:
Summary
To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
Phase:
Phase 1
Details
Lead Sponsor:
Taro Pharmaceuticals USA
Treatments:
Trifarotene